Source:http://linkedlifedata.com/resource/pubmed/id/19194832
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
2
|
pubmed:dateCreated |
2009-2-23
|
pubmed:abstractText |
In multiple myeloma (MM), it remains unclear whether the depth of response correlates with progression-free survival (PFS) and overall survival (OS). We updated long-term follow-up data on the two previously published multi-centre phase-II trials in patients with relapsed or refractory MM using thalidomide +/- IFN alpha-2B (n = 75, median follow-up 6.1 years) celecoxib-thalidomide combination (n = 66, median follow-up 4.0 years), and assessed the predictors of durable response and impact of depth of response. Twenty-seven of the 141 (19%) patients remained progression-free beyond 24 months. The most significant baseline predictor for durable PFS and OS was a serum beta(2)-microglobulin <or=3.0 mg/L. The median PFS for patients who achieved complete remission/very good partial remission, partial remission and stable disease were 69.4, 13.6 and 4.1 months, respectively (p < 0.001). The OS for these groups were >69.8, 35.4 and 11.7 months, respectively (p < 0.001). These findings support the therapeutic goal of achieving 'maximum depth of response' in patients with relapsed myeloma.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Feb
|
pubmed:issn |
1029-2403
|
pubmed:author | |
pubmed:issnType |
Electronic
|
pubmed:volume |
50
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
223-9
|
pubmed:meshHeading |
pubmed-meshheading:19194832-Adult,
pubmed-meshheading:19194832-Aged,
pubmed-meshheading:19194832-Aged, 80 and over,
pubmed-meshheading:19194832-Disease Progression,
pubmed-meshheading:19194832-Female,
pubmed-meshheading:19194832-Follow-Up Studies,
pubmed-meshheading:19194832-Humans,
pubmed-meshheading:19194832-Male,
pubmed-meshheading:19194832-Middle Aged,
pubmed-meshheading:19194832-Multiple Myeloma,
pubmed-meshheading:19194832-Recurrence,
pubmed-meshheading:19194832-Remission Induction,
pubmed-meshheading:19194832-Survival Rate,
pubmed-meshheading:19194832-Thalidomide
|
pubmed:year |
2009
|
pubmed:articleTitle |
Predicting durable remissions following thalidomide therapy for relapsed myeloma.
|
pubmed:affiliation |
Division of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, East Melbourne, VIC, Australia.
|
pubmed:publicationType |
Journal Article,
Multicenter Study,
Clinical Trial, Phase II
|